Zevra Therapeutics (NASDAQ:ZVRA) Now Covered by Analysts at BTIG Research

BTIG Research assumed coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research note published on Monday morning, MarketBeat reports. The firm issued a buy rating and a $23.00 target price on the stock.

Several other equities research analysts also recently weighed in on the company. Weiss Ratings raised Zevra Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a report on Tuesday, March 10th. HC Wainwright set a $26.00 price objective on shares of Zevra Therapeutics in a report on Tuesday, December 30th. Guggenheim set a $23.00 price objective on shares of Zevra Therapeutics and gave the company a “buy” rating in a research report on Tuesday, March 10th. Finally, Wall Street Zen cut shares of Zevra Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

Zevra Therapeutics Stock Down 1.1%

Zevra Therapeutics stock opened at $9.87 on Monday. Zevra Therapeutics has a 1-year low of $6.19 and a 1-year high of $13.16. The business has a fifty day moving average price of $8.96 and a 200-day moving average price of $9.10. The company has a debt-to-equity ratio of 0.40, a current ratio of 5.68 and a quick ratio of 5.63. The stock has a market capitalization of $579.47 million, a price-to-earnings ratio of 7.42 and a beta of 0.91.

Insider Transactions at Zevra Therapeutics

In other Zevra Therapeutics news, CEO Neil F. Mcfarlane sold 91,000 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $9.38, for a total transaction of $853,580.00. Following the sale, the chief executive officer owned 364,350 shares in the company, valued at approximately $3,417,603. The trade was a 19.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Adrian W. Quartel sold 4,533 shares of the stock in a transaction dated Friday, January 30th. The shares were sold at an average price of $8.83, for a total value of $40,026.39. Following the completion of the transaction, the insider directly owned 9,723 shares in the company, valued at $85,854.09. This represents a 31.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 114,158 shares of company stock worth $1,062,878. 2.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ZVRA. CWM LLC lifted its stake in Zevra Therapeutics by 399.5% during the 3rd quarter. CWM LLC now owns 2,872 shares of the company’s stock valued at $27,000 after acquiring an additional 2,297 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in shares of Zevra Therapeutics by 30.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock valued at $49,000 after acquiring an additional 1,280 shares during the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new stake in shares of Zevra Therapeutics in the fourth quarter worth $53,000. Russell Investments Group Ltd. increased its stake in shares of Zevra Therapeutics by 235.7% in the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after acquiring an additional 4,475 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after purchasing an additional 8,552 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.